Disclosed positions
| RELMADA THERAPEUTICS INC | RLMD | COM | $50,862,000 | 7,350,000 | SH | None |
| C4 THERAPEUTICS INC | CCCC | COM STK | $33,624,000 | 7,200,000 | SH | None |
| COGENT BIOSCIENCES INC | COGT | COM | $33,475,500 | 865,000 | SH | None |
| KODIAK SCIENCES INC | KOD | COM | $19,480,000 | 500,000 | SH | None |
| RELAY THERAPEUTICS INC | RLAY | COM | $18,148,700 | 970,000 | SH | None |
| ZENTALIS PHARMACEUTICALS INC | ZNTL | COM | $17,945,000 | 3,700,000 | SH | None |
| EDGEWISE THERAPEUTICS INC | EWTX | COM | $11,782,700 | 290,000 | SH | None |
| MAZE THERAPEUTICS INC | MAZE | COM | $9,996,400 | 335,000 | SH | None |
| INVENTIVA SA | IVA | ADS | $9,204,300 | 2,435,000 | SH | None |
| ADLAI NORTYE LTD | ANL | SPONSORED ADS | $8,796,074 | 764,876 | SH | None |
| ENLIVEN THERAPEUTICS INC | ELVN | COM | $8,120,000 | 160,000 | SH | None |
| ARRIVENT BIOPHARMA INC | AVBP | COM | $6,357,420 | 183,000 | SH | Call |
| PALISADE BIO INC | PALI | COM | $6,270,000 | 3,000,000 | SH | None |
| BIOAGE LABS INC | BIOA | COM | $6,127,500 | 250,000 | SH | Call |
| INHIBIKASE THERAPEUTICS INC | IKT | COM NEW | $6,090,000 | 3,000,000 | SH | None |
| ADAGENE INC | ADAG | ADS | $5,250,000 | 1,250,000 | SH | None |
| FORTE BIOSCIENCES INC | FBRX | COM NEW | $4,781,250 | 225,000 | SH | None |
| REZOLUTE INC | RZLT | COM NEW | $4,680,000 | 900,000 | SH | Call |
| INFLARX NV | Unresolved | COM | $4,480,000 | 2,000,000 | SH | None |
| ASSEMBLY BIOSCIENCES INC | ASMB | COM NEW | $4,396,800 | 160,000 | SH | None |
| COMPASS PATHWAYS PLC | CMPS | SPONSORED ADS | $4,315,750 | 305,000 | SH | Call |
| PROMIS NEUROSCIENCES INC | PMN | COM SHS | $4,276,697 | 324,977 | SH | None |
| CONTINEUM THERAPEUTICS INC | CTNM | CL A | $4,261,400 | 260,000 | SH | None |
| COMPASS PATHWAYS PLC | CMPS | SPONSORED ADS | $4,245,000 | 300,000 | SH | None |
| DEFINIUM THERAPEUTICS INC | DFTX | COM SHS | $3,998,400 | 85,000 | SH | None |
| SOL-GEL TECHNOLOGIES LTD | Unresolved | SHS NEW | $3,855,280 | 52,000 | SH | None |
| BIOAGE LABS INC | BIOA | COM | $3,799,050 | 155,000 | SH | None |
| SCYNEXIS INC | SCYX | COM | $3,080,518 | 756,884 | SH | None |
| PROQR THRAPEUTICS N V | PRQR | SHS EURO | $2,811,383 | 1,511,496 | SH | None |
| DISC MEDICINE INC | IRON | COM | $2,194,200 | 30,000 | SH | Call |
| REZOLUTE INC | RZLT | COM NEW | $2,097,732 | 403,410 | SH | None |
| LIPOCINE INC NEW | LPCN | COM NEW | $2,073,600 | 810,000 | SH | None |
| ZENTALIS PHARMACEUTICALS INC | ZNTL | COM | $2,066,100 | 426,000 | SH | Call |
| C4 THERAPEUTICS INC | CCCC | COM STK | $1,868,000 | 400,000 | SH | Call |
| ULTRAGENYX PHARMACEUTICAL IN | RARE | COM | $1,836,450 | 55,000 | SH | Call |
| CUE BIOPHARMA INC | CUE | COM | $1,578,000 | 50,000 | SH | None |
| CALCIMEDICA INC | Unresolved | COM NEW | $1,282,210 | 1,244,864 | SH | None |
| QUINCE THERAPEUTICS INC | QNCX | COM | $734,421 | 40,375 | SH | None |
| NUVECTIS PHARMA INC | NVCT | COM | $711,693 | 38,700 | SH | Call |
| PASITHEA THERAPEUTICS CORP | KTTA | COM NEW | $515,400 | 1,000,000 | SH | None |
| INMED PHARMACEUTICALS INC | INM | COM NEW | $503,750 | 325,000 | SH | None |
| NEUMORA THERAPEUTICS INC. | NMRA | COM | $170,000 | 100,000 | SH | None |
| NEXTCURE INC | NXTC | COM NEW | $103,142 | 64,464 | SH | None |
No matching rows. Clear the filter to see all records.
Largest 50 positions by reported value; the filing may contain more positions.
How amendments affect these holdings
This view uses 1 effective filing version(s). A restatement replaces the previous book; a new-holdings amendment adds positions. 3 positions lack a resolved ticker and 9 positions are put or call entries.
A 13F is a delayed quarterly snapshot of disclosed holdings. It is not a complete trade ledger and does not reveal every position in a manager's portfolio. Option values refer to the reported underlying position rather than a traded option premium.
Quarter end and public filing date
Use the filing's public availability date when constructing a historical observation. The quarter-end report period is earlier and cannot be substituted for when the public learned the holdings.